Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Selective activation of IFNγ-ipilimumab enhances the therapeutic effect and safety of ipilimumab" [Int. J. Biol. Macromol. 265(Pt 2) (Apr 2024) 130945].
Huang YJ, Ho KW, Cheng TL, Wang YT, Chao SW, Huang BC, Chao YS, Lin CY, Hsu YH, Chen FM, Chuang CH. Huang YJ, et al. Among authors: chen fm. Int J Biol Macromol. 2024 Oct 11;281(Pt 2):136259. doi: 10.1016/j.ijbiomac.2024.136259. Online ahead of print. Int J Biol Macromol. 2024. PMID: 39395340 No abstract available.
Corrigendum to "Selective activation of IFNγ-ipilimumab enhances the therapeutic effect and safety of ipilimumab" [Int. J. Biol. Macromol. 265(Pt 2) (Apr 2024) 130945].
Huang YJ, Ho KW, Cheng TL, Wang YT, Chao SW, Huang BC, Chao YS, Lin CY, Hsu YH, Chen FM, Chuang CH. Huang YJ, et al. Among authors: chen fm. Int J Biol Macromol. 2024 Sep 19;280(Pt 1):135670. doi: 10.1016/j.ijbiomac.2024.135670. Online ahead of print. Int J Biol Macromol. 2024. PMID: 39303493 No abstract available.
Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study.
Tseng LM, Chen FM, Chen ST, Cheng FT, Chao TY, Dai MS, Kao WY, Yeh MH, Chen DR, Liu LC, Wang HC, Chang HT, Wang BW, Yu JC, Chen SC, Liao GS, Hou MF. Tseng LM, et al. Among authors: chen fm. Oncol Res Treat. 2024;47(10):484-495. doi: 10.1159/000540369. Epub 2024 Jul 19. Oncol Res Treat. 2024. PMID: 39033747 Free article. Clinical Trial.
Discovery and characterization of dietary antigens in oral tolerance.
Blum JE, Kong R, Schulman EA, Chen FM, Upadhyay R, Romero-Meza G, Littman DR, Fischbach MA, Nagashima K, Sattely ES. Blum JE, et al. Among authors: chen fm. bioRxiv [Preprint]. 2024 May 29:2024.05.26.593976. doi: 10.1101/2024.05.26.593976. bioRxiv. 2024. PMID: 38853977 Free PMC article. Preprint.
499 results